Jagsonpal Pharmaceuticals Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/amlnv88jkke7jebawnlqaq4f.pdf

Key Takeaways


Growth Engine: Power Brands & Therapy Leadership

Medhekar: "Yes, the numbers, as Manish alluded to in the beginning, that we have been flattish at around 10% quarter 1 also and quarter 2 also. ... However, this is also lower than my own expectations. And trust me, those numbers will completely change going forward in quarter 3."

Acquisitions: Aequitas & Group Pharma Wellness

Medhekar: "The industry has moved far beyond from almost 2% contribution to in excess of around 11.5% contribution purely coming from the hospital -- corporate hospital chains. ... that's the area that we wanted to tap immediately before it becomes too late for us."

Margins: Standalone Stable, Consolidated Evolving

Gupta: "If I have to describe the last 6 months in one statement, it will be that this is a period of a bolder Jagsonpal. Not only have we scaled up our ambitions, but we are also backing it up with investments, both on organic and inorganic front, without losing sight of shareholder interest."

Strategy: Mission ₹500 Crores & Beyond

Medhekar: "We want to reduce our dependence on the acute therapy, because those are more cyclical in nature and does not bring the sustainable and predictable numbers for us."

Data Integrity & Measurement

Gupta: "I mean our internal numbers are real. That's what I would -- so I don't want to be either carried away or getting defensive about what IPM reflects because that's their data. Our data is our data. We can stand behind our data."

Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly revenue milestoneCross ₹100 crores top lineQ3 FY27
Q3 growth rateIn excess of 1.5x expected pharma industry growthQ3 FY27
Consolidated EBITDA marginVery close to 22%, if not more; definitely more than 22%Q3 FY27
Blended EBITDA marginConfident of reaching 22% mark again on blended/collective basisOngoing
Aequitas corrective action benefitsSupply chain and procurement benefits start reflecting in financialsFrom Q4 FY27 onwards
Aequitas first value-added launchNew brand commercialization end of November, go-to-market first week of DecemberQ3 FY27
Indocap innovation relaunchFirst phase go-to-market; confident of seeing at least partial results in Q3November, with Q3 impact
Aequitas FY28 top line₹100 crores; "for the full year, nothing changes for us"FY28
Mission ₹500 croresPurely organic, without further acquisitions beyond those already doneFY2028
Organic/inorganic growth splitWill add numbers for transparency, split into 2 partsOngoing disclosure
Standalone gross margin improvement50–75 bps year-on-year based on product mix and price increasesAnnual
No new product launches in other verticalsSome launches planned in Q4Q3 FY27
No manpower additionBeyond current budgeted numbersNear term

Key Metrics

MetricQ2 FY27
Standalone revenue₹81 crores, +9.3% YoY
Consolidated revenue₹96 crores, +29% YoY reflecting enlarged business contribution
H1 FY27 standalone revenue₹164 crores
H1 FY27 consolidated revenue₹179 crores
Standalone gross margin64.1% for Q2; 64.7% for H1, improvement of close to 70 bps YoY
Standalone EBITDA margin22.7% for Q2, broadly stable; 22.9% for H1, up 40 bps
Consolidated EBITDA margin19.3% for Q2
Standalone PAT₹13 crores, margin 15.5%
Consolidated PAT₹12 crores, margin 12.8%
Cash and bank balanceOver ₹135 crores
Net operating cash (consolidated, H1 FY27)₹25 crores
Organic growth (H1 FY27)9.3%
Jagsonpal growth vs IPM (Q2)~15% vs IPM growth of ~12%
Jagsonpal growth vs IPM (H1 FY27)~15% vs IPM growth of ~11%
Top 10 brands revenue contribution~58% of revenue; 9 of these rank in top 5 in their markets
Maintane growth (Q2)~29% vs molecule market growth of ~20%
Metadec growth (Q2)~14% vs market of 13%
Lycored growth (Q2)~15% vs market growth of ~13%
Endoreg growth (Q2)~20% vs market degrowth
Combined doctor reach~1,37,000 doctors post-acquisitions
MR productivity improvementUp by ~10%
Branded pure-play prescription growthUpward of 10%, contributing ~11% to 11.5%
New products contribution to growth2.3% to 2.5% of overall growth
FY26 revenue₹287 crores
FY28 revenue vision₹500 crores, purely organic without further acquisitions
Q3 FY27 revenue targetCrossing ₹100 crores, growth in excess of 1.5x expected pharma industry growth
Indocap growth (Q2)4.5%, 1% less than the market
Wellness portfolio established base (6 states)Roughly ₹1.75 crores across 2 brands
Aequitas FY28 top line guidance₹100 crores, unchanged